14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
LVRO vs EUDA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, EUDA Health Holdings Limited (EUDA) is the stronger overall head-to-head candidate over Lavoro Limited Class A (LVRO) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, R&D & Supply-Chain Moat). LVRO carries a Unified Composite Score of 41.1/100 (SELL) at $0.30 (63.7x Forward P/E, 0.2% operating margin), whereas EUDA carries 38.1/100 (SELL) at $15.96 (10.0x Forward P/E, -28.6% operating margin).
Composite vs. Pillar Nuance: While LVRO currently prints a higher short-term Unified Composite Score (41.1/100 SELL vs. EUDA 38.1/100 SELL), EUDA captures the overall institutional head-to-head verdict (5–4 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-28.6% vs. 0.2% operating margin) and revenue trajectory (+13.4% vs. -13.2% YoY).
Defensive Composite Rating Caution: Although EUDA compares more favorably head-to-head, both LVRO (41.1/100 SELL) and EUDA (38.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Technical & Structure Timing Caution: LVRO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.4); meanwhile EUDA trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 52.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on LVRO vs EUDA. Trailing 12-month operating profitability (LVRO 0.2% vs EUDA -28.6%) and valuation multiples (LVRO 63.7x vs EUDA 10.0x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Real Estate Services value chain with $52.0M market capitalization and -28.6% operating margin.
OpEx & R&D Reinvestment76.2% of Rev ($5.5M)
90D Engineering Disclosures0 Published
Investor FAQ LVRO vs EUDA Key Questions & Quantitative Answers
As of Nov 20, 2026, EUDA Health Holdings Limited (EUDA) is the stronger overall head-to-head candidate over Lavoro Limited Class A (LVRO) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, R&D & Supply-Chain Moat). LVRO carries a Unified Composite Score of 41.1/100 (SELL) at $0.30 (63.7x Forward P/E, 0.2% operating margin), whereas EUDA carries 38.1/100 (SELL) at $15.96 (10.0x Forward P/E, -28.6% operating margin). Composite vs. Pillar Nuance: While LVRO currently prints a higher short-term Unified Composite Score (41.1/100 SELL vs. EUDA 38.1/100 SELL), EUDA captures the overall institutional head-to-head verdict (5–4 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-28.6% vs. 0.2% operating margin) and revenue trajectory (+13.4% vs. -13.2% YoY). Defensive Composite Rating Caution: Although EUDA compares more favorably head-to-head, both LVRO (41.1/100 SELL) and EUDA (38.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: LVRO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.4); meanwhile EUDA trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 52.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
EUDA leads the Growth & Scale pillar: LVRO posts -13.2% YoY revenue growth and +0.0% YoY earnings growth on $9.08B TTM revenue (15.0% gross margin, 0.2% operating margin), compared with EUDA at +13.4% YoY revenue growth and +0.0% YoY earnings growth on $7.2M TTM revenue (47.6% gross margin, -28.6% operating margin). On trailing 12-month operating scale, LVRO generates $9.08B in USD-normalized revenue versus $7.2M for EUDA. In operating R&D and SG&A reinvestment, LVRO deploys 14.8% of Rev ($1.34B) (0 90-day corporate R&D disclosures) versus 76.2% of Rev ($5.5M) (0 disclosures) for EUDA.
EUDA screens cheaper on headline valuation multiples. LVRO trades at 63.7x Forward P/E, 63.7x Trailing P/E, N/M PEG, and N/M EV/Revenue (1.2% EBITDA margin), whereas EUDA trades at 10.0x Forward P/E, 7.8x Trailing P/E, N/M PEG, and 7.2x EV/Revenue (-25.5% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LVRO (-62.4% ROE) versus EUDA (-211.4% ROE) capital efficiency.
In options market volatility and institutional positioning, LVRO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.04β · 160% Vol realized risk). By comparison, EUDA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (12.05β · 113% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.